For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated

USPTO Granted Patents = 110

% Expired Patents = 1.8

EPO Patents = 1

Forward Citations = 4,023

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Leonid Beigelman (41 out of 227 patents)

Kenneth G Draper (33 out of 43 patents)

James A McSwiggen (30 out of 99 patents)

4. Nassim Usman (25 out of 32 patents)

5. Jasenka Matulic-Adamic (20 out of 29 patents)

6. Dan T Stinchcomb (19 out of 57 patents)

7. James D Thompson (16 out of 19 patents)

8. Alex Karpeisky (15 out of 17 patents)

9. Alexander Karpeisky (14 out of 28 patents)

10. Francine E Wincott (12 out of 17 patents)

11. David Sweedler (9 out of 16 patents)

12. Alex B Burgin (7 out of 8 patents)

13. Sean M Sullivan (7 out of 10 patents)

14. Thale Jarvis (6 out of 22 patents)

15. Laurent Bellon (6 out of 8 patents)

Core Competencies:

Nucleic Acid Catalysts

Enzymatic Nucleic Acids

Therapeutic RNAs

Nucleoside Analogues

RNA Polymerase III

Ribozymes

RNA Cleavage

Viral Inhibition

Gene Expression

Nucleotide Modifications

RNA Synthesis

Disease Treatment

110 patents: Sort by Forward Citations

1. 6602858 - Nucleic acid catalysts comprising L-nucleotide analogs (2003-08-05),

2. 6586238 - Enzymatic nucleic acids containing 5′-and or 3′-cap structures (2003-07-01),

3. 6555668 - Non-nucleotide containing enzymatic nucleic acid (2003-04-29),

4. 6548657 - Method for screening nucleic acid catalysts (2003-04-15),

5. 6544755 - Method and reagent for treatment of diseases by expression of the c-Myc gene (2003-04-08),

6. 6528640 - Synthetic ribonucleic acids with RNAse activity (2003-03-04),

7. 6528639 - Base-modified enzymatic nucleic acid (2003-03-04),

8. 6509460 - Nucleoside triphosphates and their incorporation into oligonucleotides (2003-01-21),

9. 6506888 - 2′-O-amino-containing nucleoside analogs and polynucleotides (2003-01-14),

10. 6492512 - Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression (2002-12-10),

11. 6489465 - Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides (2002-12-03),

12. 6482932 - Nucleoside triphosphates and their incorporation into oligonucleotides (2002-11-19),

13. 6469158 - Synthesis, deprotection, analysis and purification of RNA and ribozymes (2002-10-22),

14. 6451540 - 2′-O-alkylthioalkyl and 2′-C-alkythioalkyl containing nucleic acids (2002-09-17),

15. 6448009 - Method for target site selection and discovery (2002-09-10),

Company Overview

Ribozyme Pharmaceuticals, Incorporated, based in Boulder, Colorado, specializes in the development of nucleic acid catalysts with a focus on therapeutic applications. The company is at the forefront of research in enzymatic nucleic acids, including ribozymes and therapeutic RNAs, which have potential uses in viral inhibition and other medical therapies. Their innovative work in nucleoside analogues and RNA polymerase III further positions them as a leader in the field of nucleic acid technology, aiming to advance treatment options for various diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

110 Patents

#11 in Boulder, CO

#69 in Colorado

#3,480 in US

#7,166 in the World

Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated

Forward Citations = 4,023

56 inventors:

Leonid Beigelman (41 out of 227 patents)

Kenneth G Draper (33 out of 43 patents)

James A McSwiggen (30 out of 99 patents)

4. Nassim Usman (25 out of 32 patents)

5. Jasenka Matulic-Adamic (20 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ribozyme Pharmaceuticals, Incorporated. Retrieved from https://idiyas.com/company/ribozyme-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…